How a 19-year-old suffering from brittle bone disease beat the odds to excel academically
Tian Yanqing, from Hubei in central China, suffers from brittle bone disease, leaving her housebound for a majority of her adolescent years.
Despite numerous physical constraints, with the support of a volunteer teacher, Tian achieved a 621 in the national college entry examination in June 2025.
Advertisement
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
2 hours ago
- South China Morning Post
China forensic doctor goes viral for her muscular build, handles 600 corpses in 3 years
A forensic doctor in China who has gone viral thanks to her muscular build says she works out to perform better at work and break stereotypes about women in medicine. Yanyan, 26, is the first woman forensic pathologist to investigate sudden or suspicious deaths in a forensic science laboratory in southwestern China's Chongqing municipality. Yanyan says her muscular physique helps her perform her duties better. Photo: Baidu She has worked there for the past three years after graduating a degree in forensic medicine from Chongqing Medical University. As an experienced forensic pathologist, she has handled more than 600 bodies. On social media, she runs an account with 14,000 followers, on which she is a fitness fanatic. In the male-dominated industry, women like Yanyan are often discriminated against. Photo: Baidu Yanyan said she could dead lift 120kg, hold a chainsaw with one hand and carry out a craniotomy in three minutes.
South China Morning Post
4 hours ago
- South China Morning Post
Scientists find that the bacteria behind the plague evolved to be less deadly
Research has found that the bacteria that cause the plague evolved to become less deadly over time. This allowed it to continue infecting people in three separate pandemics over more than 1,000 years. The first plague pandemic struck in the 500s and lasted for around 200 years. The Black Death began in the mid-1300s. It was the deadliest pandemic in human history. It killed up to half of the people in Europe, western Asia and Africa, with outbreaks continuing for centuries. The third plague pandemic broke out in China in the 1850s and continues today, with some cases still being recorded in parts of sub-Saharan Africa. 'It's important to know how these outbreaks spread,' said Javier Pizarro-Cerda. He is a microbiologist at France's Pasteur Institute and co-author of a study published in May. Pizarro-Cerda and his team studied Yersinia pestis, the bacteria that cause the plague. They looked at samples from every time the pandemic happened. In all three cases, the bacteria evolved to become weaker and less deadly. By causing less severe infections, the bacteria likely made the pandemics last longer, giving them more opportunity to spread from person to person. The researchers confirmed this theory by infecting rats with recent plague samples. They found that if the plague was less harmful, the rats stayed sick for a longer time. While antibiotics can now fight off the plague, the research could help us understand how other pandemics might evolve. This will allow scientists to come up with better ways to protect humans from future plagues.
South China Morning Post
5 hours ago
- South China Morning Post
Cheaper drugs, revamped fees are healthy steps for Hong Kong
The accessible and affordable world-class public health system Hong Kong enjoys – and expects – comes at an ever-increasing price, amid an ageing society and the rising costs of medical and pharmaceutical advances. A revamp of the fee structure from next year, to recover more of the spiralling costs to the government's budget, was inevitable. Rightly, it is subject to measures to safeguard access for the most vulnerable members of society. It is good, therefore, to learn the government is going on the front foot in negotiations with pharmaceutical companies to get the best deals for many of the drugs that public patients need and the best value for the massive public investment in healthcare. As a result, patients can soon expect to pay about 20 per cent less for some drugs. Hospital Authority chief executive Dr Tony Ko Pat-sing anticipates savings to public funds of at least HK$1 billion (US$127 million) from measures including drug price reductions and expansion of sources of supplies. This is thanks in large part to a greater emphasis on a thorough procurement process. The Hospital Authority's chief pharmacist, William Chui Chun-ming, says when hospital drugs are reasonably priced, the authority can use the money saved to buy more new drugs or extend the range in stock. So far, he says, 70 per cent of drug makers, mostly from foreign countries, are willing to give discounts of an average of 20 per cent. The authority's negotiators used as a reference drug prices offered under the mainland's medical insurance system, which are generally lower due to the bargaining power of bulk procurement for a huge population. Beijing said last year that this had saved patients more than 880 billion yuan (US$123 billion). The potential for cost-effective optimisation of access to the latest pharmaceutical drugs will be enhanced by Hong Kong's aspiration to become an international medical and innovation hub, including a recognised clinical drug-trial centre. Chui said the authority would also monitor drugs in phase three clinical trials and approach developers for access to data with a view to adoption in public hospitals soon.
